Sirnaomics Revenue and Competitors

Location

$267M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Sirnaomics's estimated annual revenue is currently $7.5M per year.(i)
  • Sirnaomics's estimated revenue per employee is $100,500
  • Sirnaomics's total funding is $267M.

Employee Data

  • Sirnaomics has 75 Employees.(i)
  • Sirnaomics grew their employee count by -16% last year.

Sirnaomics's People

NameTitleEmail/Phone
1
Chief Development OfficerReveal Email/Phone
2
Chief Production OfficerReveal Email/Phone
3
VP Regulatory AffairsReveal Email/Phone
4
VP Human ResourcesReveal Email/Phone
5
Senior Director Technical Operations/EngineeringReveal Email/Phone
6
Chief Medical OfficerReveal Email/Phone
7
Senior Director ToxicologyReveal Email/Phone
8
Executive Director, Chief Scientific OfficerReveal Email/Phone
9
Chief Operation OfficerReveal Email/Phone
10
Senior Director, Bioinformatics, China CIOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7M35-3%N/AN/A
#2
$7.2M36-5%N/AN/A
#3
$10.5M52-9%N/AN/A
#4
$344.1M17129%N/AN/A
#5
$27.5M1376%N/AN/A
#6
$107.3M5349%N/AN/A
#7
$12.9M6428%N/AN/A
#8
$31.6M1571%N/AN/A
#9
$31.4M1567%N/AN/A
#10
$11.5M5730%N/AN/A
Add Company

What Is Sirnaomics?

Sirnaomics is a clinical stage biopharmaceutical company leveraging an outstanding level of knowledge and experience in RNA interference (RNAi) technology to forge a path to high value creation through discovery and development of therapeutics for human disorders with unmet medical needs. The key differentiating feature is the proprietary Polypeptide Nano-Particle (PNP) technology for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver. The clinical development pipeline is focused on oncology and fibrosis indications. Through the internal research and collaborations with prominent labs at NIH, Johns Hopkins, Duke, University of Maryland and Penn State, Sirnaomics has developed a strong portfolio of intellectual property covering RNAi therapeutic products, key biological mechanisms of action and unique PNP delivery system. The management team collectively has extensive drug development experience, as well as specialized expertise in the areas of oligonucleotide therapeutics and nanoparticle-mediated delivery.

keywords:Biotechnology

$267M

Total Funding

75

Number of Employees

$7.5M

Revenue (est)

-16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Sirnaomics News

2022-04-17 - Respiratory Rate Sensors Market Business Opportunities ...

Respiratory Rate Sensors Market Business Opportunities, Survey, Analysis And Industry Outlook | Merck & Co., Inc., Sirnaomics, NIHON KOHDEN...

2022-03-30 - Sirnaomics Doses First Subject in Phase I Clinical Trial of ...

Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the...

2022-03-30 - Sirnaomics initiates dosing in Phase I primary sclerosing ...

Sirnaomics has dosed the first healthy subject in a Phase I clinical trial analysing the potential of STP707 to treat liver fibrosis in...

2021-07-14 - Sirnaomics Doses First Patient in Phase 2 Study of STP705 for Keloid Scar Prevention

GAITHERSBURG, Md. and SUZHOU BIOBAY, China, July 14, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced dose administration for the first patient in a Phase 2 stu ...

2021-07-01 - Sirnaomics Secures $105 Million in Series E Financing

GAITHERSBURG, Md. and SUZHOU BIOBAY, China, July 1, 2021 /PRNewswire/ -- Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed $105 million in a Series E financing. This round of funding was led by Rotating Bo ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19.1M7629%N/A
#2
$11.8M76-14%$158.7M
#3
$11.6M8021%N/A
#4
$16.8M8048%N/A
#5
$18M8234%N/A